ATR and in situ carcinoma: Figure 1A reveals that under CIS conditions induced by low-dose doxorubicin (DOX+) in CIS resistant, HCT116 p53−/− (shcontrol) cells, there is little expression of activated DDR components (phospho-ATM, ATR CHK1/2).